Antipsychotic treatment strategies for acute phase and treatment resistance in schizophrenia: A systematic review of the guidelines and algorithms

被引:18
|
作者
Shimomura, Yutaro [1 ]
Kikuchi, Yuhei [1 ]
Suzuki, Takefumi [2 ]
Uchida, Hiroyuki [1 ]
Mimura, Masaru [1 ]
Takeuchi, Hiroyoshi [1 ]
机构
[1] Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo, Japan
[2] Univ Yamanashi, Fac Med, Dept Neuropsychiat, Yamanashi, Japan
关键词
Algorithms; Antipsychotics; Guidelines; Non-response; Schizophrenia; Treatment resistance; NAIVE 1ST-EPISODE SCHIZOPHRENIA; CLINICAL-PRACTICE GUIDELINES; RANDOMIZED-TRIAL; CLOZAPINE; AUGMENTATION; METAANALYSIS; MANAGEMENT; DRUGS; SCALE; RISPERIDONE;
D O I
10.1016/j.schres.2021.07.040
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: To summarize the current state of knowledge on antipsychotic treatment strategies for the acute phase and treatment resistance in schizophrenia, we conducted a systematic review of guidelines and algorithms. Methods: We conducted a systematic literature search to identify clinical guidelines and algorithms on this topic using MEDLINE and Embase. We extracted information on recommendations for antipsychotic treatment strategies, including those for non-response (i.e., increasing antipsychotic dose and switching to another antipsychotic) and treatment resistance. Results: We identified a total of 17 guidelines/algorithms in various countries that were published after 2011. With respect to antipsychotic dose, most of the guidelines (N = 10/11) agreed starting with a low dose or the lowest licensed/effective dose and then titrating the dose upwards. Regarding antipsychotic treatment strategies for non-response, all of the guidelines (N = 9/9) recommended increasing antipsychotic dose towards the upper end of its approved dose range. Five guidelines suggested for increasing beyond the therapeutic dose range in exceptional cases, while overall 10 guidelines including them were negative about such strategy. The vast majority of guidelines (N = 16/17) recommended switching to another antipsychotic for non-response; however, some guidelines mentioned the lack of evidence for these strategies other than the use of clozapine. All the guidelines (N = 17/17) endorsed initiating clozapine after failure to respond to 2 different antipsychotics. Four guidelines endorsed an early use of clozapine, yet as the third antipsychotic. Conclusion: The currently available guidelines and algorithms recommended increasing antipsychotic dose and switching to another antipsychotic, particularly clozapine for treatment-resistant schizophrenia, during the acute phase of schizophrenia for non-response.
引用
收藏
页码:142 / 155
页数:14
相关论文
共 50 条
  • [21] Inverse association between urbanicity and treatment resistance in schizophrenia
    Wimberley, Theresa
    Pedersen, Carsten B.
    MacCabe, James H.
    Stovring, Henrik
    Astrup, Aske
    Sorensen, Holger J.
    Horsdal, Henriette T.
    Mortensen, Preben B.
    Gasse, Christiane
    SCHIZOPHRENIA RESEARCH, 2016, 174 (1-3) : 150 - 155
  • [22] Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia
    Kim, Jung-Jin
    Pae, Chi-Un
    Han, Changsu
    Bahk, Won-Myong
    Lee, Soo-Jung
    Patkar, Ashwin A.
    Masand, Prakash S.
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2021, 19 (04) : 600 - 609
  • [23] Pharmacological treatment algorithms for the acute phase, agitation, and maintenance phase of first-episode schizophrenia: Japanese Society of Clinical Neuropsychopharmacology treatment algorithms
    Takeuchi, Hiroyoshi
    Takekita, Yoshiteru
    Hori, Hikaru
    Oya, Kazuto
    Miura, Itaru
    Hashimoto, Naoki
    Yasui-Furukori, Norio
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2021, 36 (06)
  • [24] Treatment Guidelines for PTSD: A Systematic Review
    Martin, Alicia
    Naunton, Mark
    Kosari, Sam
    Peterson, Gregory
    Thomas, Jackson
    Christenson, Julia K.
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (18)
  • [25] Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis
    Soares-Weiser, Karla
    Bechard-Evans, Laura
    Lawson, Anthony Howard
    Davis, John
    Ascher-Svanum, Haya
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 (02) : 118 - 125
  • [26] Antipsychotic Treatment and Mortality in Schizophrenia
    Torniainen, Minna
    Mittendorfer-Rutz, Ellenor
    Tanskanen, Antti
    Bjorkenstam, Charlotte
    Suvisaari, Jaana
    Alexanderson, Kristina
    Tiihonen, Jari
    SCHIZOPHRENIA BULLETIN, 2015, 41 (03) : 656 - 663
  • [27] Response rates to sequential trials of antipsychotic medications according to algorithms or treatment guidelines in psychotic disorders. A systematic review and meta-analysis
    O'Donoghue, Brian
    Piacenza, Francesco
    Plapp, Helena
    Siskind, Dan
    Lyne, John
    SCHIZOPHRENIA RESEARCH, 2024, 268 : 193 - 204
  • [28] Polymorphisms in Schizophrenia-Related Genes Are Potential Predictors of Antipsychotic Treatment Resistance and Refractoriness
    Zazueta, Alejandra
    Castillo, Tito
    Cavieres, Alvaro
    Gonzalez, Rene
    Abarca, Maximiliano
    Nieto, Rodrigo R.
    Deneken, Javier
    Araneda, Cristian
    Moya, Pablo R.
    Bustamante, M. Leonor
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2022, 25 (09) : 701 - 708
  • [29] A systematic review of pharmacogenetic testing to guide antipsychotic treatment
    Khani, Noushin
    Hudson, Georgie
    Mills, Georgina
    Ramesh, Soumita
    Varney, Lauren
    Cotic, Marius
    Abidoph, Rosemary
    Richards-Belle, Alvin
    Carrascal-Laso, Lorena
    Franco-Martin, Manuel
    Kaas-Hansen, Benjamin Skov
    Jurgens, Gesche
    Barrett, Barbara
    Jin, Huajie
    Bramon, Elvira
    NATURE MENTAL HEALTH, 2024, 2 (05): : 616 - 626
  • [30] World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance
    Hasan, Alkomiet
    Falkai, Peter
    Wobrock, Thomas
    Lieberman, Jeffrey
    Glenthoj, Birte
    Gattaz, Wagner F.
    Thibaut, Florence
    Moeller, Hans-Juergen
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2012, 13 (05) : 318 - 378